The partnership aims to advance high-priority small molecule programmes using Iambic’s AI models and wet lab capabilities.

Carterra Inc., the leading provider of technologies enabling high-throughput biology, today announced the launch of the ...

Iambic’s physics-informed NeuralPLexer is intended to enhance protein–ligand modeling, enabling broader exploration of ...

Scientists at the UVA Comprehensive Cancer Center say they have found a small molecule that can shut down a gene tied to glioblastoma, a discovery that could eventually point to a new way to treat ...

UVA Comprehensive Cancer Center scientists have identified a molecule that blocks the gene responsible for glioblastoma, ...

A genetics‑guided drug, compound 6, targets CARD9 to subtly calm gut inflammation in Crohn’s disease, pointing to safer, ...

UVA scientists discovered a molecule that blocks a key gene that drives glioblastoma, offering hope for a new treatment ...

Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced a multi-year technology and discovery ...

COLORADO SPRINGS, CO, UNITED STATES, January 14, 2026 /EINPresswire.com/ -- Lahjavida Bio, a biotechnology company ...

Small molecule drugs dominate new drug approvals and are crucial for treating diverse diseases. They are typically low-weight, providing easy absorption and versatile delivery methods. Their simpler ...

Immunotherapy has revolutionized cancer treatment, with immune checkpoint inhibitors (ICIs) playing a pivotal role. However, current ICIs, primarily monoclonal antibodies, face significant challenges ...

Iambic’s AI-platform includes Enchant, a multimodal transformer model designed to predict both preclinical and clinical endpoints, alongside NeuralPLexer. 1 Enchant recently received Nvidia HGX B200 ...